Form D · Pharmaceuticals
Indaptus Therapeutics, Inc.
New York, NY · CIK 0001857044
Offering snapshot reported Jun 20, 2025 · SEC filing
- Reported sold
- $2.31M Offering amount: $5M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 20, 2025 | Initial | $2,314,800 | No comparison | 20 | SEC filing |
| Jan 22, 2025 | Initial | $2,246,500 | No comparison | 16 | SEC filing |
| Dec 6, 2024 | Initial | $227,127 | No comparison | 20 | SEC filing |
| Oct 4, 2024 | Amendment | $205,480 | $0vs Aug 22, 2024 | 12 | SEC filing |
| Aug 22, 2024 | Initial | $205,480 | No comparison | 12 | SEC filing |
| Aug 5, 2021 | Initial | $30,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $600K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-549477
Offering of convertible notes in the aggregate principal amount of up to $5 million, convertible into shares of common stock, together with warrants to purchase shares of common stock. Approximately $2.3 million raised as of initial closing date.
The Issuer paid the placement agent (i) 12% of gross proceeds in the offering, (ii) a $25,000 non-accountable expense and (iii) a number of warrants equal to 12% of the shares issuable upon conversion of the notes sold in the offering.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Paulson Investment Company, LLC | 000005670 |
Source: Form D, filed Jun 20, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark J. Gilbert | Director |
| William B. Hayes | Director |
| Hila Karah | Director |
| Hoonmo Lee | Director |
| Walt A. Linscott | Executive |
| Anthony J. Maddaluna | Director |
| Robert E. Martell | Director |
| Jeffrey A. Meckler | Director, Executive |
| Michael J Newman | Director, Executive |
| Brian O'callaghan | Director |
| Roger J. Pomerantz | Director |
| Nir Sassi | Executive |
| Roger J. Waltzman | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3 Columbus Circle
New York, NY, 10019
Phone: (646) 427-2727
New York, NY, 10019
Phone: (646) 427-2727